NRG1: An Emerging Tumor Agnostic Target

Gain expert insight into the emerging role of NRG1 fusions as rare oncogenic drivers in a variety of solid tumors and learn about the targeted therapies in development from expert commentaries, a text-based module, and a downloadable slideset.

Maria E. Arcila, MD

Joshua Sabari, MD

ClinicalThought

NRG1 Oncogenic Gene Fusions Across Solid Tumors: What You Should Know About Testing

View ClinicalThought

Read this commentary from Maria E. Arcila, MD, on the recommendations for testing for NRG1 fusions in patients with solid tumors.

Maria E. Arcila, MD Released: November 16, 2021

ClinicalThought

NRG1 Oncogenic Gene Fusions Across Solid Tumors: Emerging New Agents for an Important Target

View ClinicalThought

Expert commentary by Joshua Sabari, MD, on the role of NRG1 fusions in solid tumors and the emerging targeted therapies for patients harboring this oncogenic alteration.

Joshua Sabari, MD Released: February 28, 2022